It can be difficult to distinguish between people with normal age-associated memory loss and those with amnestic mild cognitive impairment (aMCI). However people with aMCI are at a greater risk of developing Alzheimer's disease (AD), and identification of these people would mean that they could begin treatment as early as possible. New research published in BioMed Central's open access journal BMC Geriatrics shows that specific questions, included as part of a questionnaire designed to help diagnose AD, are also able to discriminate between normal memory loss and aMCI.
Loss of memory can be distressing for the person affected and their families and both the patient and people who know them may complain about their memory as well as difficulties in their daily lives. However memory problems can be a part of normal aging and not necessarily an indicator of incipient dementia. A pilot study had indicated that a simple, short, questionnaire (AQ), designed to identify people with AD by using informant-reported symptoms, was also able to recognize people with aMCI.
The AQ consists of 21 yes/no questions designed to be answered by a relative or carer in a primary care setting. The questions fall into five categories: memory, orientation, functional ability, visuospatial ability, and language. Six of these questions are known to be predictive of AD and are given extra weighting, resulting in a score out of 27. A score above 15 was indicative of AD, and between 5 and 14 of aMCI. Scores of 4 or lower indicate that the person does not have significant memory problems.
While validating the AQ researchers from Banner Sun Health Research Institute discovered that four of the questions were strong indicators of aMCI. Psychometrist Michael Malek-Ahmadi, who led the study, explained, "People with aMCI were more often reported as repeating questions and statements, having trouble knowing the date or time, having difficulties managing their finances and a decreased sense of direction." He continued, "While the AQ cannot be used as a definitive guide to diagnosing AD or aMCI, it is a quick and simple-to-use indicator that may help physicians determine which individuals should be referred for more extensive testing."
Dr Hilary Glover
Scientific Press Officer, BioMed Central
Notes to Editors
1. Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment. Michael Malek-Ahmadi, Kathryn Davis, Christine Belden, Sandra Jacobson and Marwan N Sabbagh. BMC Geriatrics (in press)
Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.
Article citation and URL available on request at firstname.lastname@example.org on the day of publication.
2. BMC Genomics is an open access, peer-reviewed journal that considers articles on all aspects of genome-scale analysis, functional genomics, and proteomics.
3. BioMed Central (http://www.
4. For 24 years, Sun Health Research Institute, part of nonprofit Banner Health, has been a leader nationally and internationally in the effort to find answers to disorders of aging including Alzheimer's disease, Parkinson's disease. The institute, together with its Arizona Alzheimer's Consortium partners, has been designated by the National Institutes of Health as one of just 29 Alzheimer's Disease Centers in the nation. The institute's Cleo Roberts Center for Clinical Research takes laboratory discoveries to clinical trials that foster hope for new treatments. Banner Health is Arizona's leading health care provider and second largest private employer. For more information, visit http://www.